Quick search:
Content Search
Result Content Research
Result Content Research
1 Polyphor Provides Update on the Phase III FORTRESS Study of
2 Balixafortide and Eribulin Shows Modest Responses in Patients with HER2-Negative Breast Cancer
3 FDA Grants Balixafortide Fast Track Designation for Treatment of Metastatic Breast Cancer Subset
4 Polyphor announces enrollment of first patient in FORTRESS Phase III clinical trial for balixafortide in combination with eribulin in patients with metastatic breast cancer
5 Polyphor Announces Financial Results for the Full-Year 2020
6 Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activity in COVID-19 Preclinical
7 Setback for Polyphor's breast cancer candidate balixafortide
8 Balixafortide Plus Eribulin Fails to Improve ORR in Advanced HER2-Negative Breast Cancer
9 Polyphor Announces Closing of Fosun Pharma Licensing
10 Polyphor to Present at the UBS Global Healthcare Virtual Conference
11 Polyphor Temporarily Halts Enrollment in the Phase III Studies of Murepavadin for the Treatment of Patients With Nosocomial Pneumonia
12 Polyphor Hosting Key Opinion Leader Roundtable on Covid-19:
13 Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin
14 Plerixafor for mobilization in stem cell transplantations | JBM
15 Polyphor presents new data at ECCMID from its lead antibiotic murepavadin and the new OMPTA POL7306
16 EQS-Adhoc: Polyphor presents final update of the FORTRESS Phase III study with balixafortide in patients with HER2-negative advanced breast cancer Page 1